Denali Therapeutics Inc (DNLI) Valuation

DNLI Valuation & Fair Value Analysis

Denali Therapeutics Inc (DNLI) valuation analysis using multiple fair value methodologies. GoodMoat calculates a blended fair value target using discounted cash flow (DCF) analysis, the Graham Number, and earnings-based valuation models.

The price-to-earnings (P/E) ratio is -5.81. Price-to-book ratio is 2.91. PEG ratio is 0.50.

GoodMoat's valuation models include the Graham Number (based on EPS and book value), an earnings-based model (discounted future EPS), and a PEG-adjusted valuation. The three models are averaged to produce a blended fair value estimate. Use these tools alongside the DCF calculator and reverse DCF to form a comprehensive view of Denali Therapeutics Inc's intrinsic value.